Navigation Links
Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
Date:1/15/2009

rage 15% annual growth).

Full-year results will be markedly improved compared to 2007, which will enable the Group to finance its development plans while maintaining a positive free cash flow for the fourth consecutive year.

As regards 2009, the Group remains prudent and currently provides guidance of sales growth between 8 and 10%. 2009 will also feature a number of significant clinical test results as part of the Oralair programme.

Significant 4th quarter transactions and events

Oralair(R) Grasses quarterly sales in Germany were in line with expectations. The marketing authorization for the use Oralair(R) Grasses on children, which should be delivered very soon by the German agency, will set the European mutual recognition procedure of the product in motion.

On October 27, 2008, Stallergenes obtained authorization (IND) from the FDA for the use of Oralair(R) Grasses in clinical trials in adults. This study is proceeding satisfactorily.

In order to exert better control over its operations in Switzerland and Austria, Stallergenes has launched a procedure aiming at having subsidiaries distribute its products in these two countries from the start of 2009. At the end of this procedure, Stallergenes will have a subsidiary in Austria and its current distributor in Switzerland, TRIMEDAL, will join the Stallergenes Group.

Corporate governance

At today's meeting, the Board of Directors took note of the AFEP/MEDEF recommendations of October 6, 2008 on the remuneration of directors of listed companies. The Board considers that these recommendations are consistent with the Company's corporate governance policy and gave the Remuneration Committee the responsibility to carry out a detailed review of the rules governing their implementation within the Group.

Consequently, the Board of Directors confirms in principle that in application
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
2. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
3. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
4. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
5. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
6. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
7. BIO 2008: Germany on Cutting Edge in Biomanufacturing
8. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
9. Commencement 2008: Student innovation could improve data storage, magnetic sensors
10. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
11. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 Research ... the addition of Jain PharmaBiotech,s new report ... and Companies" to their offering. ... This report deals with therapeutic drug monitoring, ... patient care by monitoring drug levels in ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
(Date:5/28/2015)... 2015 DryLet, LLC a biotechnology ... such as animal waste reduction, bioremediation, wastewater treatment, ... wastewater treatment plants and restaurant kitchen settings, announced ... Expo, June 3-5 in Des Moines, Iowa. , ... Wall Street Journal article because of its industry-leading ...
(Date:5/28/2015)... 28, 2015  GenVec, Inc. (Nasdaq: GNVC ) ... J. Swirsky , will present a company overview at ... EDT on Thursday, June 4, 2015. ... will be available at the following link:  http://wsw.com/webcast/jeff88/gnvc ... website.  To access, visit www.genvec.com , click on ...
Breaking Biology Technology:Global Therapeutic Drug Monitoring Market 2015-2024 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2GenVec To Present At The Jefferies Healthcare Conference 2
... sensing by a team of Rensselaer Polytechnic Institute researchers ... agents and illegal drugs from a distance of 20 ... wave technology, has great potential for homeland security and ... packaging materials and can identify immediately the unique THz ...
... pressing concerns of the day, fear of plague probably isn,t ... whose responsibility it is to combat bioterrorism, plague is among ... like medical researcher Steve Smiley, whose lab at the Trudeau ... the public against weaponized forms of plague. The Institute, which ...
... 15 Precision Therapeutics announced today that its ... recognized as CEO of the Year by the ... http://photos.prnewswire.com/prnh/20101015/NE83126 ) (Photo: http://www.newscom.com/cgi-bin/prnh/20101015/NE83126 ... recognizes the accomplishments of 50 of southwestern Pennsylvania,s ...
Cached Biology Technology:A revolutionary breakthrough in terahertz remote sensing 2Plague researchers race to beat bioterrorists 2Plague researchers race to beat bioterrorists 3Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year 2
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... that died 44,000 years ago in Antarctica have provided ... traditional genetic aging measurements, and suggest those approaches have ... 200 to 600 percent. In other words, a ... 100,000 years old may actually be 200,000 to 600,000 ...
... -- Agricultural soils accumulate trace metals, particularly copper ... wastes (sewage biosolids and manures) and fungicides that are ... for tolerable concentrations of these potentially plant-toxic elements in ... effects of the metals are substantially independent and not ...
... and LAS VEGAS, Nov. 9 CBS Vision, the ... Media Group company, today announced a new research partnership that will ... housed in the MGM Grand Hotel in Las Vegas. , ... one of the county,s leading agencies, will be called Communications ...
Cached Biology News:Ancient penguin DNA raises doubts about accuracy of genetic dating techniques 2Additive copper-zinc interaction affects toxic response in soybean 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 2CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 3CBS and OMD Partner to Provide the Agency With Access to the Network's Television City Research Facility in Las Vegas 4
WNV Core Antibody...
HSD17B3 Immunogen: HSD17B3 (NP_000188, 29 a.a. ~ 120 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rad51, N-terminal...
Phospho-mu-Opioid Receptor (Ser375) Antibody...
Biology Products: